A PCDH15 or CLRN1 Carrier Flag for Usher Syndrome: What the Research Actually Says

A PCDH15 or CLRN1 Carrier Flag for Usher Syndrome: What the Research Actually Says

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A carrier result is not a diagnosis. Research is consistent that Usher syndrome is autosomal recessive, so a person needs two changed copies of the same gene to be affected. One flagged variant leaves a healthy carrier with typical hearing and typical retinas. A child is at risk only when the other biological parent carries a variant in that same gene. Even then, the chance is 25 percent per pregnancy. A 2025 genomic analysis estimates overall prevalence at about 1 in 29,000 people. Consumer carrier reports are regulated as screening tests that are “not intended to diagnose a disease”. The honest next step is a certified genetic counselor, not a search-engine spiral.

What you’ll learn:

• Why a single carrier variant does not put your own hearing or vision at risk
• The gene-matching rule most pages skip, and how it changes your family’s real odds
• How a consumer screen differs from a clinical diagnostic panel in the US and Canada
• Where the treatment landscape genuinely stands in 2026, without the hype

What Usher Syndrome Is: Hearing, Balance, and Vision in One Condition

Usher syndrome links two senses that most conditions affect separately. It causes hearing loss and, later, a slow retinal disease called retinitis pigmentosa. The Usher Syndrome Coalition calls it the most common genetic cause of combined deafness and blindness. NIDCD, part of the National Institutes of Health, reports that it represents “about 50 percent of all hereditary deaf-blindness cases”.

One condition affects both ear and eye for a molecular reason. MedlinePlus Genetics names at least eleven genes behind Usher syndrome, including MYO7A, CDH23, USH2A, CLRN1, ADGRV1, PCDH15, USH1C and WHRN. These genes build proteins the body needs in the sensory cells of the inner ear and in the light-sensing cells of the retina.

Here is one everyday analogy. Imagine a specialised cable that a factory uses on two different production lines. If the supplier fails, both lines stall, even though the lines make different products.

Clinicians sort Usher syndrome into three types by hearing, balance and night vision. The table below quotes NIDCD’s own descriptions.

Type	Hearing at birth	Balance	Night vision	Genes named
Type 1	“Profound hearing loss or deafness at birth”	“Balance problems from birth”	“Decreased night vision by age 10”	MYO7A, USH1C, CDH23, PCDH15, USH1G
Type 2	“Moderate to severe hearing loss at birth”	“Normal balance”	“Decreased night vision by adolescence”	USH2A, ADGRV1, WHRN
Type 3	“Progressive hearing loss in childhood or early teens”	Normal to near-normal in childhood	“Night vision problems often begin in teens”	CLRN1

GeneReviews, the expert clinical resource hosted by the National Center for Biotechnology Information, adds precision. It defines type 1 as “congenital bilateral profound sensorineural hearing loss, vestibular areflexia, and adolescent-onset retinitis pigmentosa”. Vestibular areflexia means the inner-ear balance organ gives no response. Within type 1, MYO7A accounts for 60 to 70 percent of cases and PCDH15 for 7 to 15 percent.

Type 2 looks different. GeneReviews describes a sloping audiogram, milder in low frequencies and severe in high ones, with balance usually intact. USH2A accounts for most type 2 cases, followed by ADGRV1 and WHRN.

The word “blindness” also needs care. The National Eye Institute reports that “loss of night vision” is the usual first symptom of retinitis pigmentosa. Vision then narrows toward the centre, a pattern often called tunnel vision. Progression varies between people, and it is not a sudden loss of all sight.

If a relative has both hearing loss and night vision trouble, raise that pattern with a clinician. An audiologist and a retinal specialist can evaluate it properly. A certified genetic counselor can be found through the NSGC Find a Genetic Counselor directory, which covers the United States and Canada.

Section recap: Usher syndrome affects hearing, balance and vision because the same genes serve the inner ear and the retina. Three clinical types differ in severity and timing.

Autosomal Recessive Inheritance: What a Carrier Result Does and Does Not Mean

This is the most important section for a healthy adult holding a carrier report. MedlinePlus Genetics puts it plainly. All types of Usher syndrome are inherited in an autosomal recessive pattern, “which means both copies of a gene in each cell have a mutation”.

A carrier has one changed copy and one working copy. The working copy still does its job. So carriers have typical hearing and typical retinas, and a carrier result is reproductive information rather than a personal health forecast.

Think of a car with two independent brake circuits. If one fails, the other still stops the car. Only when both fail does the car lose braking.

When two people carry a variant in the same gene, GeneReviews gives the recurrence figures for each pregnancy:

• 25 percent (1 in 4): the child inherits two changed copies and is affected.
• 50 percent (1 in 2): the child is a healthy carrier, like both parents.
• 25 percent (1 in 4): the child inherits two working copies.
• Every pregnancy resets: these are independent odds, not a quota that gets used up.

Now the rule that most top-ranking pages omit. Recessive disease needs two hits in the same gene. Someone carrying a PCDH15 variant and a partner carrying a CLRN1 variant cannot have a child with Usher syndrome from those two variants. The changes sit in different genes, so neither gene ends up with two broken copies.

This matters because Usher syndrome is genetically diverse. A 2025 genomic analysis states that “nine genes have been conclusively linked to Usher syndrome”. Two carriers are a risk pair only when their variants land in one shared gene.

Some variants are more common in specific ancestries because of founder effects. A founder variant spreads through a population descended from a small ancestral group. GeneReviews reports that the PCDH15 variant c.733C>T “is detected in a large percentage of Ashkenazi Jewish individuals with PCDH15-USH1”. That variant was described in the New England Journal of Medicine in 2003. A separate 2003 study identified a CLRN1 founder variant, N48K, in Ashkenazi Jewish families with Usher type 3. This pattern is why consumer panels include these particular variants.

Being a carrier is not a diagnosis and not a reason to change your own medical care. It is a reason to have one structured conversation with a genetic counselor before family planning decisions.

Section recap: Carriers are healthy. Usher syndrome needs two changed copies of one gene, so a PCDH15 carrier and a CLRN1 carrier are not a risk pair.

How Common Is Usher Syndrome: Turning Prevalence Into an Honest Number

Two NIH sources agree. NIDCD states that “Usher syndrome affects approximately 4 to 17 per 100,000 people”. MedlinePlus Genetics gives the same range and adds that types I and II are the most common forms in most countries.

A 2025 population-scale genomic analysis refined that estimate using large variant databases. It calculated prevalence for all subtypes at “1 in ~29,000,” which works out to “30,405 individuals in the United States”. The same study estimates that “324 babies in the United States and 12,090 worldwide are born with Usher syndrome each year”.

Estimates differ for a reason worth understanding. Milder and later-diagnosed cases are easy to miss. GeneReviews notes a hearing-loss cohort in Oregon where prevalence “may be as high as one in 6,000” by that route. GeneReviews also puts type 2 prevalence at about 4.4 per 100,000 in the general US population.

Carrier frequency is the number that drives your family’s math. Retrieved sources report the following:

• All Usher genes combined: “1% of control subjects carry a pathogenic USH variant”.
• USH2A: the most prevalent single gene, “at 1 in 150 individuals”.
• PCDH15: carrier frequency about 1 in 469 generally, and “1 in 72 to 1 in 238 (Ashkenazi Jewish)”; MYO7A is about 1 in 193.
• CLRN1 N48K: “the carrier frequency of N48K was 0.7% (95% CI 0 to 1.6%) among Ashkenazi Jews from the New York area”.

Those figures convert into a per-pregnancy answer in two steps. Take the chance that the partner carries a variant in the same gene, then multiply by 25 percent. Nothing else changes the arithmetic.

Start with a PCDH15 carrier and a partner of unrelated ancestry. Using the general-population figure of 1 in 469, the arithmetic gives roughly 1 in 1,880 per pregnancy. That is about 0.05 out of 100 pregnancies. Now use the reported Ashkenazi range instead. The arithmetic gives roughly 1 in 290 to 1 in 950, or about 0.1 to 0.35 out of 100 pregnancies.

Both numbers are small, and both are arithmetic built on published averages rather than a personal result. Only actual partner testing replaces an average with a fact, and a genetic counselor should walk you through that step.

One caution about a reassuring result. A consumer report analyzes a defined variant list, and the FDA device regulation requires manufacturers to publish which genes and variants the test detects. A “variant not detected” result lowers your carrier probability but never drives it to zero. It also says nothing about genes that were never on the list, and MedlinePlus names far more Usher genes than any consumer panel reports.

Section recap: Usher syndrome affects roughly 4 to 17 per 100,000 people, and about 1 in 29,000 by genomic modeling. Real per-pregnancy risk hinges on partner testing in the same gene.

Testing in the US and Canada: Consumer Screen Versus Clinical Diagnostic Panel

The line between screening and diagnosis is written into US law. Direct-to-consumer carrier reports fall under 21 CFR 866.5940, a Class II device regulation with special controls. That rule says the device “is intended for autosomal recessive disease carrier screening in adults of reproductive age”.

The required consumer warnings are blunt. An over-the-counter test must state that it “is not intended to diagnose a disease, or tell you anything about your risk for developing a disease in the future”. It must also state that the test is “not a substitute for visits to a healthcare provider.” Another required warning notes that “your ethnicity may affect how your genetic health results are interpreted”. The rule even requires manufacturers to help buyers reach “a board-certified clinical molecular geneticist or equivalent” for counseling.

Clinical testing is a different product with a different purpose.

	Consumer carrier screen	Clinical diagnostic testing
Purpose	Screening in adults of reproductive age	Etiologic diagnosis and clinical management
Scope	A defined, published variant list	Comprehensive gene panel, exome or genome
Legal status	“Not intended to diagnose a disease”	Interpreted by a board-certified laboratory professional
How you order it	Directly, online	Through a physician or genetic counselor
What a negative means	Lower, not zero, residual risk	Depends on panel content and method

The professional standard on where testing belongs is explicit. The 2015 ACMG and AMP consensus recommends that clinical molecular genetic testing be performed in a laboratory approved under the Clinical Laboratory Improvement Amendments. It adds that results should be interpreted by a board-certified clinical molecular geneticist or equivalent. That is the basis for confirming any consumer result before it drives a decision.

Two technical realities matter before ordering anything. First, nine genes are conclusively linked to Usher syndrome, so a panel covering only some of them cannot rule out the rest. Second, the ACMG 2022 clinical practice resource notes that overlapping presentations of hearing loss challenge traditional clinical evaluation. Genetic testing exists precisely to cut through that overlap.

Access differs by country. In the United States, testing usually runs through a medical genetics, ENT or ophthalmology clinic, and coverage varies by plan. In Canada, services are organised provincially rather than nationally. The 2024 national report card on early hearing detection found that “seven out of 13 Canadian provinces/territories do not provide sufficient infant hearing health care”. That is a useful illustration of how uneven provincial delivery can be, so confirm what your own province offers.

In both countries, bring the consumer report to a clinician or counselor and ask what clinical test, if any, is warranted. The NSGC directory offers in-person and telehealth searches, which helps when relatives live in different provinces or states.

Section recap: A consumer carrier report is a regulated screening test that cannot diagnose. Clinical confirmation belongs in a CLIA-certified laboratory ordered through a clinician.

Reading the Result: Affected, Carrier, or Variant of Uncertain Significance

Laboratory reports use a five-category vocabulary. The 2015 ACMG and AMP standards recommend the terms “pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”. Classification weighs population data, computational data, functional data and segregation data.

Three outcomes cover almost every reader:

• Two pathogenic variants in one Usher gene, with symptoms: this points to a genetic diagnosis. Clinical confirmation still follows, including visual acuity, visual field testing, electroretinography, optical coherence tomography, audiometry and tympanometry.
• One variant in one gene: carrier status, and healthy.
• A variant of uncertain significance: not a diagnosis and not a clearance. It can be reclassified later as evidence accumulates.

Because the framework is evidence-weighted, classifications get revisited. The PubMed record for the 2015 standards lists many later comments and clarifications, which shows the framework is actively maintained. Ask the ordering laboratory about its reclassification and re-contact policy.

Interpretation can be more technical than a consumer report suggests. A 2024 report of a Chinese family with Usher type 3 shows this sharply. The same DNA change read as c.474T>A (p.Cys158Ter) on one CLRN1 transcript, but as c.302T>A (p.Val101Asp) on another. The authors concluded that “pathogenicity of different transcripts should be particularly considered”. One change, two predicted protein consequences, depending on the reference the laboratory used.

The gene name alone does not fix the outlook either. GeneReviews notes that MYO7A also causes the non-syndromic hearing loss forms DFNA11 and DFNB2. It adds that less damaging USH1C variants may cause deafness without retinitis pigmentosa. Even one founder variant does not guarantee a single clinical course. In the 2003 Ashkenazi Jewish cohort, “N48K homozygotes displayed a wide range of phenotypic severities”.

There is one genuinely powerful use of genetic testing here. A hearing-loss panel can identify Usher syndrome years before any vision symptom appears. The ACMG resource states that identifying the cause of hearing loss “may affect clinical management, improve prognostic accuracy, and refine genetic counseling”.

Think of variant classification as a court case rather than a coin flip. Evidence accumulates, and the verdict can change. Do not read a laboratory report alone. A genetic counselor or medical geneticist reads it against your family history.

Section recap: Reports use five classification categories, and uncertain findings are common. Interpretation is transcript-dependent and technical, so it belongs to a clinical laboratory and counselor.

Early Detection and the Care Pathway That Already Exists

This section carries the most practical value, especially for families with a deaf or hard-of-hearing child. The United States already runs a system that catches the presenting feature of Usher type 1 in infancy.

NIDCD reports that “universal newborn hearing screening programs currently operate in all U.S. states and most U.S. territories,” and that “about 98% of babies have their hearing screened before 1 month of age”. It adds that two or three of every 1,000 US children are born with detectable hearing loss.

The timing benchmarks come from the Joint Committee on Infant Hearing. Its 2019 position statement describes the 1-3-6 benchmark: screening by 1 month, audiologic diagnosis by 3 months, and early intervention by 6 months. States already meeting that standard “should strive to meet a 1-2-3 month timeline”.

• Screening is a first step, not the whole system. It “does not ensure the next critical steps of timely identification and diagnosis”.
• A normal newborn screen does not settle the question. JCIH explicitly recognises delayed-onset and progressive hearing loss in infants. That is why Usher type 3, where hearing starts near normal, can pass a newborn screen.
• Canada is provincial, not uniform. The 2024 report card graded Canada’s infant hearing services “Insufficient”.
• Genetic testing belongs in the workup, because knowing the cause guides management and counseling.

Two red flags should prompt a family to ask about Usher syndrome by name. The first is delayed independent walking with poor balance. GeneReviews reports that “children with USH1 typically walk later than usual, at approximately age 18 months to two years,” and older children “may seem ‘clumsy'”. It adds that these children are often misdiagnosed with non-syndromic hearing loss until delayed walking or night blindness becomes noticeable. The second flag is later-onset night blindness in a deaf or hard-of-hearing child or teenager.

Ongoing management is structured and already exists. GeneReviews recommends annual ophthalmologic evaluation before visual symptoms begin, using fundus photography, acuity, visual fields, electroretinography and optical coherence tomography. For type 2, it recommends annual eye evaluation from age 20 to detect “cataracts, refractive errors, and cystoid macular edema”. Those three are treatable complications, which is the whole point of surveillance.

GeneReviews also lists circumstances to approach carefully. Progressive peripheral vision loss “impairs the ability to safely drive a car,” submerged swimming carries disorientation risk, and bright sunlight and tobacco smoking “can accelerate progression”. On the device side, approved care is rehabilitative: hearing aids, cochlear implants and low-vision services. The National Eye Institute notes that low vision aids and rehabilitation programs help people with retinitis pigmentosa make the most of their vision.

One supplement deserves a careful paragraph. The National Eye Institute states that “vitamin A may help slow vision loss from the common forms of RP.” It immediately adds that “taking too much vitamin A can cause liver problems”. That is a possibility with a safety caveat, not established Usher therapy. GeneReviews is firmer for one group, warning that high-dose vitamin A “should not be used by affected pregnant women” because large doses may be teratogenic. Nobody should start high-dose vitamin A without a retinal specialist’s decision.

One note on tone comes from the ACMG resource itself. It observes that linguistic and cultural identities tied to being deaf or hard-of-hearing can complicate access to care, and that culturally sensitive delivery reduces that friction. Deafness is an identity as well as a clinical finding, and good care respects both.

Section recap: Newborn hearing screening plus genetic evaluation can surface Usher syndrome years before vision symptoms. Scheduled retinal surveillance catches treatable complications.

Treatment Landscape in 2026: What Is Approved and What Is Still Investigational

The honest headline is short. There is no FDA-approved and no Health Canada-approved disease-modifying or curative therapy for Usher syndrome of any type. A Health Canada Drug Product Database query for products branded for Usher syndrome returned an empty result set. Approved care remains device-based and rehabilitative.

A common misconception needs correcting here. Voretigene neparvovec, sold as Luxturna, is a real approved gene therapy, but not for Usher syndrome. Its FDA label limits it to “confirmed biallelic RPE65 mutation-associated retinal dystrophy,” with initial US approval on December 19, 2017. In Canada it is marketed under DIN 02505851, with an original market date of March 14, 2022, under the same RPE65 restriction. It does not treat retinitis pigmentosa caused by MYO7A, PCDH15, CLRN1 or USH2A.

Investigational work is real, early, and narrower than headlines suggest. Registry facts retrieved from ClinicalTrials.gov carry the weight here.

Program	Gene target	Registry status
AAVB-081 dual AAV8.MYO7A, Phase 1/2	MYO7A, type 1B only	NCT06591793, RECRUITING; started 2024-07-02; estimated enrollment 15
QR-421a (Stellar), Phase 1/2	USH2A exon 13	NCT03780257, COMPLETED
Ultevursen (Sirius), Phase 2/3	USH2A exon 13	NCT05158296, TERMINATED
QR-421a (Celeste), Phase 2/3	USH2A exon 13	NCT05176717, TERMINATED
Ultevursen, Phase 2	USH2A exon 13	NCT06627179, ACTIVE_NOT_RECRUITING

Several details in that table matter more than any press release. The MYO7A study has a single primary outcome measure, described as the number and severity of treatment-related adverse events. Efficacy is a secondary objective, so this is a first-in-human safety study rather than an efficacy trial. Its registered sites are in Italy and the United Kingdom, with no US or Canadian site listed. It targets MYO7A only, and not PCDH15 or CLRN1.

One sponsor-reported item needs an explicit label. On January 16, 2026, Foundation Fighting Blindness reported an announcement from the trial sponsor, AAVantgarde Bio. The company said the study had “enrolled 15 adult participants, aged 18 to 60” across three dose levels. That report contains no efficacy data, no visual-function measurements and no safety outcomes. Completing enrollment is a milestone in study conduct. It is not evidence of benefit, and it is a sponsor statement rather than a regulatory finding.

The antisense picture is similarly sobering. The pivotal Phase 2/3 studies of that approach were terminated, while a Phase 2 study remains active and not recruiting. No antisense product has reached approval. Those programs also target USH2A exon 13, so they are not relevant to a PCDH15 or CLRN1 carrier result.

• No gene therapy for PCDH15 or CLRN1 has reached approval anywhere.
• Early-phase results are preliminary and are not a treatment offer.
• NEI describes gene, cell and drug therapies for retinitis pigmentosa as experimental research.
• A registry option exists: NCT02435940, an inherited retinal degenerative disease registry that lists Usher syndrome among its conditions.

If a family member is affected and wants trial information, the route is a retinal specialist plus ClinicalTrials.gov, not a company website. A specialist can assess eligibility honestly, including travel to a foreign trial site.

Section recap: As of 2026 no disease-modifying therapy for Usher syndrome is approved by the FDA or Health Canada. Luxturna covers RPE65 only, and gene-therapy work remains early phase.

Family, Insurance, and the Emotional Weight in the US and Canada

A carrier result is family information, not just personal information. If a result is confirmed, at least one parent carries the same variant. Because each parent passes one of two copies, each full sibling has roughly a 50 percent chance of carrying it too. If a child in the family is affected, each later sibling has a 25 percent chance of being affected and a 50 percent chance of being a carrier.

That arithmetic makes telling siblings a practical act rather than an alarm. Mention it to a doctor before planning a pregnancy.

Reproductive planning options exist and are counselor-guided rather than self-selected. The starting point is always the same. Test the partner in the same gene first, because that single step decides whether any risk exists. A genetic counselor can then explain the options available in your jurisdiction and clinic.

Legal protections differ across the border, and the difference is significant.

• US health insurance: under GINA Title I, “health insurers may not use genetic information to determine if someone is eligible for insurance.” The same bar applies to “coverage, underwriting or premium-setting decisions”.
• US employment: GINA Title II bars employers from using genetic information in hiring, firing, promotion and pay, and from requiring genetic tests as a condition of employment.
• The US gap: GINA does not cover life insurance, disability insurance or long-term care insurance, and does not apply to employers with fewer than 15 employees.
• US state law: GINA is a floor, not a ceiling, and states may be stricter, as California did with CalGINA in 2011.
• Canada, broader scope: the Genetic Non-Discrimination Act prohibits requiring a genetic test, or its disclosure, as a condition of providing goods, services or agreements.
• Canada, consent: the Act also bars collecting, using or disclosing genetic test results in those activities without written authorization.

Canada’s law reaches further than GINA does. It is not limited to health insurance and employment, so it also touches contracts such as life insurance. Penalties are serious. On indictment they run to “a fine not exceeding $1,000,000 or to imprisonment for a term not exceeding five years”.

That law survived a constitutional challenge. The Supreme Court of Canada decided Reference re Genetic Non-Discrimination Act, 2020 SCC 17, on July 10, 2020. In the Court’s own summary, “Parliament had the power to make it a crime to force someone to get genetic testing or reveal their test results.” Its example is the one families ask about. Insurance companies “couldn’t make people get tested to get life insurance coverage”.

The emotional side deserves equal weight. Progressive vision loss layered on deafness raises real questions about communication access, mobility, driving and when to tell a child. Scheduled eye evaluations address the driving question directly, because they advise on ability to drive as peripheral vision changes.

Support structures exist for both loads. The NSGC directory lists over 3,300 genetic counselors across the United States and Canada, with in-person and telehealth options. NSGC notes that it “is not a referral service” but a list of its members, so treat it as a starting point. The Usher Syndrome Coalition maintains the USH Trust registry, described as “a simple, confidential, and free database of individuals who have Usher syndrome”. That registry is for people who have the condition, so a healthy carrier is not its target population. Foundation Fighting Blindness publishes research news for the retinal disease community.

Whatever the report says, do not carry the interpretation alone. A counselor’s job is to convert a document into a plan for your specific family.

Section recap: Siblings share carrier odds, so disclosure is practical. GINA protects US health coverage and employment but not life insurance, while Canada’s law reaches contracts more broadly.

Frequently Asked Questions

Does carrying one PCDH15 variant cause deafness or blindness? No. Usher syndrome is autosomal recessive, so both copies of a gene must be affected. A carrier has one working copy and is expected to have typical hearing and typical retinas. Existing hearing or vision symptoms are a separate clinical question for an audiologist or ophthalmologist.

Will the children of a carrier inherit Usher syndrome? Only if the other biological parent also carries a variant in the same gene. In that case each pregnancy carries a 25 percent chance of an affected child. With general-population carrier figures, the arithmetic lands well under 1 out of 100 pregnancies. Partner testing replaces the estimate with a fact.

Can this result affect health or life insurance? In the United States, GINA bars health insurers from using genetic information in eligibility, coverage, underwriting or premium decisions. GINA does not cover life, disability or long-term care insurance. In Canada, the Genetic Non-Discrimination Act restricts requiring a test or its disclosure as a condition of a contract, and the Supreme Court upheld it in 2020.

Can an employer find out? GINA prohibits US employers from using genetic information in hiring, firing, promotion or pay, and from requesting genetic tests as a condition of employment. Employers with fewer than 15 employees fall outside GINA, though some states add protections. In Canada, requiring disclosure of test results as a condition of services or agreements is prohibited.

Is a second opinion or confirmatory test worth it? Yes, before any reproductive or medical decision. Key reasons:

• A consumer carrier report is regulated as a screening test that is “not intended to diagnose a disease”.
• Professional guidance places clinical testing in a CLIA-approved laboratory with board-certified interpretation.
• A certified genetic counselor can order confirmatory testing and read it against family history.

Section recap: Carriers stay healthy, children are at risk only through a same-gene partner, and legal protections differ between the US and Canada. Confirm anything consequential with a clinician.

Summary

A carrier flag for Usher syndrome reads like a verdict and is not one. The condition is autosomal recessive, so a person needs two changed copies of the same gene to be affected. One variant leaves a healthy carrier.

• The gene-matching rule: a PCDH15 carrier and a CLRN1 carrier are not a risk pair, because recessive disease needs both hits in one gene.
• The real odds: a matched carrier couple faces 25 percent per pregnancy, not a certainty. Prevalence is roughly 4 to 17 per 100,000, and about 1 in 29,000 by genomic modeling.
• The testing order: a consumer report screens a limited variant list and cannot diagnose; clinical confirmation belongs in a CLIA-approved laboratory.
• The actionable win: newborn hearing screening plus genetic evaluation can find Usher syndrome years before retinal symptoms begin.
• The treatment truth: no disease-modifying therapy is approved by the FDA or Health Canada, and Luxturna covers RPE65 only.

Meanwhile, surveillance already delivers real benefit. Scheduled retinal evaluations, audiology care and low-vision rehabilitation catch treatable complications and protect function. Gene-therapy and antisense programs remain early phase, with sponsor statements kept separate from registry facts.

You also have rights and support. GINA and Canada’s Genetic Non-Discrimination Act each limit how genetic information can be used, with different gaps. The most useful next step is an appointment with a certified genetic counselor. Bring the report, ask whether your partner should be tested in the same gene, and let the research rather than the fear set the pace.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. National Institute on Deafness and Other Communication Disorders (NIDCD), NIH. Usher Syndrome. https://www.nidcd.nih.gov/health/usher-syndrome
2. MedlinePlus Genetics, National Library of Medicine (NIH). Usher syndrome. https://medlineplus.gov/genetics/condition/usher-syndrome/
3. Redfield, Mauriac, Geleoc, Shearer (2025). A Genomic Analysis of Usher Syndrome: Population-Scale Prevalence and Therapeutic Targets. American Journal of Medical Genetics Part C 199(3):218-227. PMID 40248902; PMC12353266; DOI 10.1002/ajmg.c.32142. https://pubmed.ncbi.nlm.nih.gov/40248902/
4. Ness, Ben-Yosef, Bar-Lev, Madeo, Brewer, Avraham, Kornreich, Desnick, Willner, Friedman, Griffith (2003). Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III. Journal of Medical Genetics 40(10):767-772. PMID 14569126; PMC1735287; DOI 10.1136/jmg.40.10.767. https://pubmed.ncbi.nlm.nih.gov/14569126/
5. Ben-Yosef, Ness, Madeo, Bar-Lev, Wolfman, Ahmed, Desnick, Willner, Avraham, Ostrer, Oddoux, Griffith, Friedman (2003). A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome. New England Journal of Medicine 348(17):1664-1670. PMID 12711741; DOI 10.1056/NEJMoa021502. https://pubmed.ncbi.nlm.nih.gov/12711741/
6. US Food and Drug Administration. 21 CFR 866.5940 — Autosomal recessive carrier screening gene mutation detection system (current text via eCFR). https://www.ecfr.gov/current/title-21/section-866.5940
7. LUXTURNA (voretigene neparvovec-rzyl) — FDA prescribing information, via DailyMed, National Library of Medicine. Initial US approval December 19, 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08313a24-e7ce-457a-bb3f-161bc45517ee
8. Health Canada, Drug Product Database (queried 2026). Voretigene neparvovec, DIN 02505851, marketed since March 14, 2022; no product authorized for Usher syndrome. https://health-products.canada.ca/dpd-bdpp/
9. ClinicalTrials.gov (NIH/NLM). NCT06591793 — Phase 1/2 study of subretinal dual AAV8.MYO7A (AAVB-081) in Usher syndrome type IB retinitis pigmentosa. https://clinicaltrials.gov/study/NCT06591793
10. ClinicalTrials.gov (NIH/NLM). USH2A exon 13 antisense oligonucleotide records: NCT03780257, NCT05158296, NCT05176717, NCT05085964, NCT06627179; and inherited retinal degenerative disease registry NCT02435940. https://clinicaltrials.gov/study/NCT06627179
11. National Institute on Deafness and Other Communication Disorders (NIDCD), NIH. Your Baby’s Hearing Screening. https://www.nidcd.nih.gov/health/your-babys-hearing-screening
12. National Eye Institute, NIH. Retinitis Pigmentosa. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/retinitis-pigmentosa
13. Wang, Xu, Zhu, Ding, Hu, Xu, Guo, Liu (2024). A rare transcript homozygous variants in CLRN1 (USH3A) causes Usher syndrome type 3 in a Chinese family. Orphanet Journal of Rare Diseases. PMID 39304915; PMC11414144; DOI 10.1186/s13023-024-03348-x. https://pmc.ncbi.nlm.nih.gov/articles/PMC11414144/
14. Government of Canada, Justice Laws Website. Genetic Non-Discrimination Act (S.C. 2017, c. 3). https://laws-lois.justice.gc.ca/eng/acts/G-2.5/page-1.html
15. Supreme Court of Canada. Reference re Genetic Non-Discrimination Act, 2020 SCC 17 (Case in Brief, file 38478, judgment July 10, 2020). https://www.scc-csc.ca/case-dossier/cb/2020/38478-eng.pdf
16. National Human Genome Research Institute (NHGRI), NIH. Genetic Discrimination — Genetic Information Nondiscrimination Act of 2008 (GINA). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
17. Koenekoop, Arriaga, Gillies, Trzupek, Lentz. Usher Syndrome Type I. GeneReviews, University of Washington / NCBI Bookshelf (last update June 9, 2026). https://www.ncbi.nlm.nih.gov/books/NBK1265/
18. Koenekoop, Arriaga, Trzupek, Lentz. Usher Syndrome Type II. GeneReviews, University of Washington / NCBI Bookshelf (last revision March 23, 2023). https://www.ncbi.nlm.nih.gov/books/NBK1341/
19. Li, Abou Tayoun, DiStefano, Pandya, Rehm, Robin, Schaefer, Yoshinaga-Itano; ACMG Professional Practice and Guidelines Committee (2022). Clinical evaluation and etiologic diagnosis of hearing loss. Genetics in Medicine 24(7):1392-1406. PMID 35802133; DOI 10.1016/j.gim.2022.03.018. https://pubmed.ncbi.nlm.nih.gov/35802133/
20. Richards, Aziz, Bale, Bick, Das, Gastier-Foster, Grody, Hegde, Lyon, Spector, Voelkerding, Rehm; ACMG and AMP (2015). Standards and guidelines for the interpretation of sequence variants. Genetics in Medicine 17(5):405-424. PMID 25741868; PMC4544753; DOI 10.1038/gim.2015.30. https://pubmed.ncbi.nlm.nih.gov/25741868/
21. Joint Committee on Infant Hearing (2019). Year 2019 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs — Executive Summary. https://www.jcih.org/JCIH_2019_Executive_Summary.pdf
22. Canadian Infant Hearing Task Force (Canadian Academy of Audiology and Speech-Language & Audiology Canada), May 28, 2024. 2024 National Report Card on Early Hearing Detection and Intervention in Canada. https://www.sac-oac.ca/more-one-third-canadian-infants-not-access-sufficient-infant-hearing/
23. National Society of Genetic Counselors (NSGC). Find a Genetic Counselor directory. https://findageneticcounselor.nsgc.org/
24. Usher Syndrome Coalition. What is Usher Syndrome? / The USH Trust Registry. https://www.usher-syndrome.org/what-is-usher-syndrome/
25. Foundation Fighting Blindness (January 16, 2026), reporting an AAVantgarde Bio announcement (sponsor-reported). AAVantgarde Completes Enrollment in Retinal Gene Therapy Trial for Usher Syndrome Type 1B. https://www.fightingblindness.org/news/aavantgarde-completes-enrollment-in-retinal-gene-therapy-trial-for-usher-syndrome-type-1b-3346

Last updated: 2026-08-20

Author: genelumen editorial team. This article aggregates 25 sources from peer-reviewed medical literature and public health agencies (tier 1=16 / tier 2=8 / tier 3=1), including NIH (NIDCD, NEI, NHGRI, MedlinePlus), GeneReviews, ClinicalTrials.gov, the FDA, Health Canada, ACMG guidelines, and PubMed-indexed publications. Editorial responsibility: Yu Mizuno, a non-physician research editor.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911.

Related: Neurogenetic Diseases category

🌐 日本語版: https://genelumen.com/ja/ja-neurogenetic/usher-syndrome-pcdh15-clrn1-guide